Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Reports Preliminary Q1 Revenues of $549M to $554M, Beating Analyst Expectations

NEW YORK – Bruker announced after the close of the market on Tuesday that it anticipates Q1 2021 revenues of $549 million to $554 million, which would represent year-over-year growth of approximately 30 percent to 31 percent.

On average, analysts are expecting Q1 revenues of $506.9 million.

The company said the performance was driven by double-digit organic year-over-year revenue growth across all three of its Bruker Scientific Instrument groups, including the placement of two GHz-class NMR systems.

Bruker estimated non-GAAP organic revenue growth of 22 percent to 23 percent for Q1 2021, up from its previous projection of greater than 15 percent organic growth for the quarter.

In Wednesday morning trading on Nasdaq, Bruker shares were up a fraction of a percent to $69.14.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more